CONTENTS:
- Alibi marketing? Surrogate marketing? Brand sharing? What is the correct terminology to discuss marketing for alcohol-free and low-alcohol products which share branding with regular strength alcohol products? [Editorial]. Critchlow N., Holmes J., Fitzgerald N., p. 4-6.
- Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: A systematic review. Gregory C., Yadav K., Linders J., Sikora L., Eagles D., p. 7-20.
- Commentary on Gregory et al.: Fear of precipitated opioid withdrawal should not prevent buprenorphine initiation. Springer S.A., p. 21-22.
- Surveillance of alcohol use through population surveys in the Americas from 2010 to 2019. Jaswal H., Sohi I., Chrystoja B., Imtiaz S., Franklin A., Wettlaufer A., et al., p. 23-47.
- Predictors of substance use during treatment for addiction: A network analysis of ecological momentary assessment data. Serre F., Gauld C., Lambert L., Baillet E., Beltran V., Daulouede J.P., et al., p. 48-58.
- Commentary on Serre et al. : Demonstrating the next era of addiction science. Stone B.M., Thrul J., p. 59-60.
- Affective dynamics surrounding craving, non-heavy alcohol use and binge drinking in female patients with alcohol use disorder and controls: An experience sampling method study. Leenaerts N., Vaessen T., Sunaert S., Ceccarini J., Vrieze E., p. 61-76.
- Alcohol use as a predictor of intimate partner violence in emerging adulthood: A dyadic daily diary investigation. Shorey R.C., Dunsiger S.I., Stuart G.L., p. 77-85.
- Effect of a small increase in off-premises trading hours on alcohol sales in Norway: A stepped-wedge cluster-randomized controlled trial. Bergsvik D., Grotting M.W., Rossow I., p. 86-94.
- Effect of nicotine mouth spray on urges to vape: A randomized, placebo-controlled, pharmacodynamic clinical trial in exclusive e-cigarette users. Danielsson T., Bennet H., McColgan B., Wang J., p. 95-105.
- Effectiveness of mobile smoking cessation treatment with 1-week nicotine replacement therapy sampling at outdoor smoking hotspots: A cluster randomized controlled trial. He W.J.A., Wang Q., Chan C.H.H., Luk T.T., Wang M.P., Chan S.C.S., et al., p. 106-115.
- Mapping consumptions and market size of cocaine, amphetamine and MDMA through wastewater analysis: A Dutch case study. Ter Laak T.L., Emke E., Dolot N., van Loon E.E., van der Kooi M.M.E., van Asten A.C., et al., p. 116-125.
- Commentary on ter Laak et al.: The importance of drug market information and differentiating drug use patterns. Verhagen R., Thai P.K., p. 126-127.
- Comparison of strength and adulteration between illicit drugs obtained from cryptomarkets versus off-line. Coney L., Peacock A., van der Gouwe D., Smit-Rigter L., Hutten N., Ventura M., et al., p. 128-137.
- Medications for opioid use disorder: Predictors of early discontinuation and reduction of overdose risk in US military veterans by medication type. Hayes C.J., Raciborski R.A., Nowak M., Acharya M., Nunes E.V., Jr., Winhusen T.J., p. 138-151.
- Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient- and prescriber-level characteristics in Massachusetts, USA. Young G.J., Zhu T., Hasan M.M., Alinezhad F., Young L.D., Noor E.A.M., p. 152-163.
- The association between state cannabis policies and cannabis use among adults and youth, United States, 2002-2019. Pessar S.C., Smart R., Naimi T., Lira M., Blanchette J., Boustead A., et al., p. 164-170.
- Commentary on Pessar et al.: 'Downscaling' United States state cannabis policy to investigate environmental and social impacts on cannabis use. Mennis J., Stahler G.J., Mason M.J., p. 171-173.
- Tailored text-messaging versus standard Quitline telephone counselling for smoking cessation among people who smoke from a low-socio-economic status background in Australia: A study protocol for a non-inferiority randomized controlled trial (The Quit By Phone Study). Howard B.C., Donnelly S., McRobbie H., Barker D., Petrie D., Stockings E., et al., p. 174-183.
- Implications of the shift to DSM-5 for alcohol use disorder prevalence estimates in the National Survey on Drug Use and Health. Bailey A.J., Quinn P.D., McHugh R.K., p. 184-188.
- Public health considerations about tetrahydrocannabinol-infused beverages. LoParco C.R., Tillett K.K., Chen-Sankey J., Berg C.J., Rossheim M.E., p. 189-190.